20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

ITPP in Oncology: Reversing Tumor Hypoxia for Better Treatment Outcomes

Tumor hypoxia is a complex and multifaceted challenge in oncology. The often chaotic and inefficient vasculature within tumors leads to areas of low oxygen concentration, which not only promotes tumor growth and invasiveness but also confers resistance to various therapies, including chemotherapy and radiation. Consequently, strategies aimed at reversing tumor hypoxia are of significant interest in developing more effective cancer treatments. Myo-Inositol Trispyrophosphate (ITPP), identified by CAS 802590-64-3, is one such compound showing considerable promise in preclinical studies.

ITPP's mechanism of action, as an allosteric effector of hemoglobin that enhances oxygen release, directly addresses the issue of oxygen deficit. By increasing oxygenation within the tumor microenvironment, ITPP can potentially overcome the resistance mechanisms associated with hypoxia. Preclinical research suggests that this improved oxygen supply can sensitize tumor cells to chemotherapy and may even normalize the tumor vasculature, making it more amenable to drug delivery. For oncologists, researchers, and pharmaceutical developers working in this field, sourcing high-quality ITPP is a critical step. When you plan to buy ITPP for oncology research or drug development, it is imperative to ensure the material meets high purity standards. Partnering with a reliable ITPP supplier, especially one with manufacturing capabilities in China, can provide access to consistent, high-grade material.

The potential of ITPP as an adjunct therapy in cancer treatment is an active area of investigation. Its ability to reverse tumor hypoxia opens new avenues for therapeutic strategies. Pharmaceutical companies and research institutions seeking this critical intermediate should engage with experienced manufacturers who can offer competitive pricing and assured supply. By securing a dependable source for ITPP, the scientific community can further explore its potential to improve treatment outcomes for cancer patients.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: ITPP for Cardiovascular Health: Enhancing Oxygen Delivery

Next: Why 3-Fluorobenzoic Acid is a Key Intermediate for Pharma and Agrochemicals

All Rights Reserved